In this article, we are going to take a look at where Moderna, Inc. (NASDAQ ... with all major indices finishing in the red, driven by losses in technology stocks. The Nasdaq dropped 0.51% ...

If you've been following my research, you'd know that I specialize in small and some mid-cap biotech (i.e., SMID ... Operating out of Cambridge, Massachusetts, Moderna was founded for over ...

By the end of the third week of February, your investment would be in the red ... Moderna's valuation at its peak likely seemed exceptionally frothy to some. A $37 billion market cap for a ...

The current scenario where Moderna is valued at more than half of Pfizer's market cap should be only temporary. On the other hand, the uncertainty about the recurring revenue for COVID-19 vaccines ...

JP Morgan has downgraded its valuation of Moderna, saying its $37 billion market cap is way too high even if its COVID-19 vaccine mRNA-1273 succeeds in clinical trials. Moderna’s share price has ...

Moderna, a mRNA-based vaccine developer, has risen by a healthy 158% over the first five months of 2020. The excitement around this mid-cap biotech stock centers on its experimental COVID-19 ...

We recently published a list of 12 High Growth Large Cap Stocks to Buy Now. In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands against other high growth ...

Thanks to its mRNA Covid vaccine, Moderna now is a household name ... and Rubius (market cap $1.3 billion), which uses red blood cells as treatments for cancer and autoimmune diseases.

Moderna stock fell 21.31% amid pressure on vaccine stocks after President-elect Donald Trump nominated Robert F. Kennedy Jr. to lead the HHS XPeng shares dipped 16.89%, reflecting a broader trend ...